Your shopping cart is currently empty

TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $392 | In Stock | In Stock | |
| 5 mg | $726 | In Stock | In Stock | |
| 10 mg | $987 | In Stock | In Stock | |
| 25 mg | $1,620 | - | In Stock | |
| 50 mg | $2,190 | - | In Stock | |
| 100 mg | $2,960 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $893 | - | In Stock |
| Description | TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia. |
| Targets&IC50 | FGFR2:157 nM, FGFR4:4045 nM, FGFR1:278 nM, FGFR3:11 nM |
| Synonyms | TYRA-300-B01, TYRA300 |
| Molecular Weight | 559.47 |
| Formula | C25H24Cl2N6O3S |
| Cas No. | 2800223-30-5 |
| Smiles | S(C)(=O)(=O)N1CC2(CN(C2)C3=CC=C(C=N3)C=4C=5C(NN4)=CC=C(O[C@H](C)C=6C(Cl)=CN=CC6Cl)C5)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (268.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (8.94 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.